Inflammatory bowel diseases (IBD) manifest not only in the gastrointestinal (GI) tract, but also affect joints, skin, eyes, liver, lung, and pancreas. Up to half of patients with IBD have extraintestinal manifestations (EIMs) of IBD. Therapies for intestinal inflammation are not sufficient to treat EIMs such as anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis (PSC), which usually occur independent of disease flares. In the October issue of Gastroenterology, Gerhard Rogler et al review the epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in patients with IBD.
Trending
- This is your doctor on ChatGPT (Business Insider)
- Experts’ Practices Vary in Managing Barrett Esophagus (Medscape)
- 6 Gastroenterology Headlines You Missed in October 2025 (HCP Live)
- The Clinician’s Guide to Breaking Into Digital Health (Massively Better Healthcare)
- UnitedHealthcare pays Optum doctors more than other doctors: study (Healthcare Dive)
- American Gastroenterological Association and MATTER welcome 11 startups to inaugural incubator (MATTER)
- Tri Century Eye Care & Pittsburgh Gastroenterology Associates Announce Data Breaches (The HIPAA Journal)
- Five ways for independent GI practices to prepare for payment cuts (AGA)
